Loading...
•
Dec 31, 2021
Leap Therapeutics Q4 2021 Earnings Report
Leap Therapeutics reported financial results for Q4 2021, featuring updates on DKN-01 development and strategic collaborations.
Key Takeaways
Leap Therapeutics reported Q4 2021 financial results, highlighting DKN-01 development and a strategic collaboration with BeiGene. License revenues were $0.4 million. Research and development expenses were $8.1 million, and general and administrative expenses were $2.8 million. Cash and cash equivalents totaled $114.9 million at the end of the year.
Leap Therapeutics presented positive data from the DisTinGuish clinical trial, demonstrating efficacy in G/GEJ cancer patients with high tumoral DKK1 expression.
The company is well-funded to advance DKN-01 into the next stages of development in G/GEJ and other cancers.
Leap Therapeutics will present updated data from the DisTinGuish Study in the second half of 2022.
DKN-01 modulates the Wnt/Beta-catenin and PI3kinase/AKT signaling pathways, playing a role in tumor cell signaling.
Leap Therapeutics
Leap Therapeutics
Forward Guidance
Leap Therapeutics is focused on developing targeted and immuno-oncology therapeutics and expects to advance DKN-01.
Positive Outlook
- Advancing DKN-01 into next stages of development.
- Presenting updated data from the DisTinGuish Study in the second half of 2022.
- Strategic collaboration with BeiGene for DKN-01 development in Asia (excluding Japan), Australia, and New Zealand.
- DKN-01 is in clinical trials in patients with esophagogastric, hepatobiliary, gynecologic, and prostate cancers.
- Well funded to advance DKN-01
Challenges Ahead
- Clinical trials may not have an effective design or generate positive results.
- Potential delays or adverse effects due to COVID-19 related issues.
- Unstable global market and economic conditions.
- Uncertainties in the clinical development process.
- Ability to obtain and maintain regulatory approval of drug product candidates.